MARKET

ANRO

ANRO

Alto Neuroscienc
NYSE
2.780
-0.100
-3.47%
After Hours: 2.780 0 0.00% 16:04 07/18 EDT
OPEN
2.900
PREV CLOSE
2.880
HIGH
2.910
LOW
2.740
VOLUME
83.09K
TURNOVER
--
52 WEEK HIGH
17.55
52 WEEK LOW
1.600
MARKET CAP
75.26M
P/E (TTM)
-1.1846
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ANRO last week (0707-0711)?
Weekly Report · 4d ago
Weekly Report: what happened at ANRO last week (0630-0704)?
Weekly Report · 07/07 12:16
H.C. Wainwright Reaffirms Their Buy Rating on Alto Neuroscience, Inc. (ANRO)
TipRanks · 06/30 16:15
Alto Neuroscience highlights study results guiding ALTO-207 development
TipRanks · 06/30 14:53
Analysts Are Bullish on Top NA Stocks: Alto Neuroscience, Inc. (ANRO), Rapport Therapeutics, Inc. (RAPP)
TipRanks · 06/30 12:30
Weekly Report: what happened at ANRO last week (0623-0627)?
Weekly Report · 06/30 12:26
Alto Neuroscience Highlights Lancet Psychiatry Publication Of PAX-D Study Showing Antidepressant Efficacy Of Pramipexole In TRD Despite Tolerability Limitations
Benzinga · 06/30 12:06
Alto Neuroscience Highlights Peer-Reviewed Publication of PAX-D Study in The Lancet Psychiatry Demonstrating Robust Clinical Effects of Pramipexole for Patients with Treatment-Resistant Depression
Barchart · 06/30 07:03
More
About ANRO
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company focused on redefining psychiatry by leveraging neurobiology to develop personalized and effective treatment options. The Company's Precision Psychiatry Platform measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to identify which patients are likely to respond to its product candidates. Its clinical-stage pipeline includes drug candidates in bipolar depression, major depressive disorder, treatment resistant depression (TRD), and schizophrenia, and other mental health conditions. Its product candidates include ALTO-100, ALTO-300, ALTO-207, ALTO-203, ALTO-101, ALTO-202, and ALTO-208. ALTO-100 is a first-in-class, oral small molecule believed to work through enhancing neural plasticity in the hippocampus, a brain region important for both cognition and mood. ALTO-203 is an oral small molecule histamine H3 receptor inverse agonist.

Webull offers Alto Neuroscience Inc stock information, including NYSE: ANRO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANRO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ANRO stock methods without spending real money on the virtual paper trading platform.